Luspatercept-aamt (Reblozyl)

Reblozyl (luspatercept‑aamt) is covered only for adults (≥18) with beta thalassemia who require regular RBC transfusions and is not covered for oncology or other non–FDA‑approved (off‑label) indications. Coverage requires hematologist prescription/consultation, documentation of diagnosis/age/transfusion history and weight, dosing ≤1.25 mg/kg SC no more frequently than every 3 weeks, initial approval for 4 months and 12‑month renewals only if there is a clinically meaningful decrease in transfusion burden.

"Treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions."

Sign up to see full coverage criteria, indications, and limitations.